Monday, May 23, 2011 – After Market Close

Green Baron New “Stock Pick”

“2011 Stock Pick of the Year”

Nuvilex, Inc.

(OTCQB: NVLX – $.059 per share)

www.Nuvilex.com

Common Shares Outstanding / 353.0M

Market Cap / $20.8M

2011 Year High / $.076

2011 Year Low / $.012

Average Volume / 993,623 (50-day) 552,843 (200-day)

 

New Experienced Management Completes Reorganization with Focus on Cutting Edge Areas of Biotechnology; Plan to Also Advance Existing Portfolio of 14 Patents Includes Products Entering Multi-Billion Dollar Markets

Breaking News: May 19, 2011 - Nuvilex, Inc. in Advanced-Stage Discussions to Acquire Pancreatic Cancer Treatment Technology

CEO of Nuvilex, Dr. Robert F. Ryan: "owning this advanced therapeutic technology, Nuvilex will become a significant player in the biotechnology arena …”

Green Baron Agrees that Price Target of .50 per Share by Year-End Set by Goldman Small Cap Research on May 10 is Clearly in Reach

Everyone loves a turnaround story, and The Green Baron Report has just discovered what we believe will be a turnaround story for the ages. Now, after attracting two successful PhD’s to become its CEO and COO earlier this year and a successful reorganization, we are proud to introduce a stock that we believe will thrive in the coming months and years.

The Green Baron Report officially selects Nuvilex, Inc. (OTCQB: NVLX) our 96^th Green Baron “Stock Pick” since inception, and our “2011 Stock Pick of the Year”.  Results compiled from the most recent trade prior to dissemination of this report to the subsequent high will be closely monitored at www.thegreenbaron.com and through email updates to members.  We have very aggressive price projections for NVLX and believe the stock has huge upside potential based on several positive fundamental and technical factors.

Why?  After lengthy discussions with management and existing shareholders, we determined that Nuvilex will generate tremendous revenue growth from new formulations of existing products, new marketing / distribution agreements of those products, entrance into hot sectors of the biotech industry, introduction of blockbuster eco-friendly products over the next 18 months, and complete targeted intelligent acquisitions that will impress investors.  We are impressed with new management and believe they can successfully guide this Company on a path to unbridled success.  The shareholder base appears very supportive and contains some very influential and well-known names. 

This has all led us to select Nuvilex, Inc. (OTCQB: NVLX) as our “2011 Stock Pick of the Year” and agree that NVLX could go to at least .50 by year-end.

TRADER’S NOTES:   Significant accumulation demonstrated by record high trading volumes over the past two weeks for the stock have propelled NVLX from .03 to as high as .076 per share.  A research report released on May 10 by Goldman Small Cap Research appeared to ignite interest in the stock when it issued a target price of .50 per share by year end.  NVLX appears to be consolidating between .055 and .075 per share and we believe it will break out any day above the year high for a move to double digit levels.

NVLX has a 10-day average volume of over two million shares and a 50-day average volume of nearly one million shares.  We view this active volume as providing fantastic liquidity for traders, and a great opportunity to accumulate a decent position at a fair price.  NVLX is represented by a long list of market makers and ECN’s that tend to keep the spread to within a tenth of a cent or less most of the day. 

Nuvilex has a deep research and development portfolio in the natural products segment, and is leveraging its knowledge into potentially blockbuster biotechnology products.  The Company’s primary offerings are in the estimated $150 billion natural products industry including popular natural supplements.  Nuvilex has been awarded 14 patents for a number of its formulations and its broad product line is sold via the Web and in major stores. 

The Green Baron Report believes that NVLX stock is just beginning to make its move higher.  Here are several reasons why we would own NVLX now and for the long term:

·         Pancreatic Cancer Treatment Technology – This acquisition will enable Nuvilex to provide encapsulated, living cells engineered to target tumors in patients with minimal collateral tissue damage. In completed clinical studies on pancreatic cancers, this treatment protocol has been shown to double life expectancy over present conventional pancreatic cancer therapy.  We anticipate this treatment technology to receive much more attention once the acquisition is officially completed, and could provide a nice bump to NVLX stock at that time. 

·         Successful Reorganization: New management additions of CEO Dr. Robert Ryan and COO Dr. Gerald Crabtree bring contacts and knowledge that are critical to product development, redevelopment, and acquisitions.  Early on, they formed a new marketing & sales department, restructured pricing to enhance gross profit margins, and made plans to release new packaging / sizes for Cinnergen.  It is noted that Dr. Ryan purchased 5 million shares of restricted stock in Nuvilex at a premium when he joined the Company. 

·         Patented Blockbuster “Green” Cleaner product Citroxin™ - This innovative eco-friendly, antimicrobial, sterilizer and cleanser offers huge direct and private label sales potential through a market opportunity that is about $10 billion a year.  Nuvilex is in the final stages of approval with the EPA to market the product and hopes to receive this approval in the second half of 2011.

·         Oraphyte™ - All Natural Formula to Protect Lawns and Crops – Here is yet another product that would enter a billion dollar industry.  This non-toxic, biodegradable proprietary combination of organic materials is highly effective in combating bacteria that is harmful to grass and plant growth. It has the potential to replace methyl bromide and other extremely hazardous chemicals presently being used.

·         Growth of Existing Line of Nutraceutical and Cosmetic Products – Nuvilex owns a product designed to aid diabetics or pre-diabetic individuals, a product that maintains normal cholesterol levels / normal cardiovascular functions, a product to prevent and treat symptoms of flu, and more.  It also owns a product known to heal scars and one that is a tattoo ink engineered to be permanent yet is far easier to remove if desired.  All these products may be retained and used to drive growth, or can be sold off to raise cash to focus on businesses with even more upside growth.

·         Anti-Cancer Agent Alternia™ - Initial studies, carried out at a prestigious research center in Georgia, suggested Alternia™ had potential to cause alterations in cell division and initiate apoptosis in cancer cells, a series of events typically leading to cell death.  Continued successful development of Alternia™ should raise the valuation and profile for Nuvilex.

·         Goldman Small Cap Research Targets .50  – Analyst Rob Goldman’s original report issued just a few weeks ago on May 10 stated that NVLX is “valued for its current portfolio only, so investors get the rest of the Company for free” and “does not reflect the expected launch of new products or the value of the pre-clinical development portfolio.” The report rates Nuvilex a Speculative Buy adding “we believe that the shares could reach $0.50 by year end.”  A more recent update issued on May 19 added that “underlying value increasing yet again with latest news.”

Why buy now after recent move up?  We have reason to believe that Nuvilex management will deliver impressive results and discover new ways to enhance shareholder value.  We believe investors are only just beginning to notice the recent reorganization, and its best moves are still coming.  Some of our contacts thought the announcement of its acquisition of the pancreatic cancer treatment would cause NVLX to more than double from .07 per share.  We believe that the closing of that acquisition will give investors more to cheer about. 

The Green Baron Report predicts that NVLX could hit .25 per share by the end of June, and will be headed even higher during the summer.  Management has indicated that it is pursuing the most cutting-edge growth areas in the biotechnology arena.  We like the direction of NVLX, and we are confident that triple digit percentage gains are coming over the near-term.

About Nuvilex, Inc.

Nuvilex is a Green Company believing in “Good for You, Good for the Environment” and is expanding its natural product lines and making important strides to enter into biotechnology.  Current products include Cinnergen™ for healthy glucose maintenance; Cinnechol™ to maintain healthy lipids and cardiovasculature; Talsyn™ for keloids, erythema, and scar management; NumaDerm™ cosmetic products; Citroxin™ and Oraphyte™ antimicrobial and antinematodal agents; Reme-Flu™, Legacy Biotechnologies’ flu combating regimen; and Virgin® and Infinitink®, heavy-metal-free tattoo inks.

Following a recently completed reorganization, Nuvilex has set an agenda to acquire the most cutting-edge growth areas in the biotechnology arena.  A planned acquisition involves therapeutic treatment potential for pancreatic cancer, an aggressive, invasive disease responsible for 37,000 annual deaths in the U.S. alone. This acquisition will enable Nuvilex to provide encapsulated, living cells engineered to target tumors in patients with minimal collateral tissue damage.

Current Products

Cinnergen
Cinnergen is a liquid whole food nutritional supplement that enhances your diet by providing the vital nutrients many of which are deficient or may be missing altogether from a normal diet your body needs to properlymetabolize sugar and use it as energy. The whole food concentrates in Cinnergen include amino acids, vitamins, minerals, trace minerals, enzymes, bioflavonoids, antioxidants and several phyto chemicals, all of which are beneficial to the body. Better still, Cinnergen delivers these nutrients in proper proportion for the body to use them immediately.

Cinnergen delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. One of the main reasons blood sugar imbalances occur is because the typical diet is not only high in sugar but also deficient in several of the vital nutrients the body needs to properly process sugar and turn it into energy. If these nutrients are not provided by the foods we eat, our bodies are forced to leach them from elsewhere in the system. As a whole food complex, Cinnergen provides several key ingredients that have been found through emerging science and years of research to improve digestion and utilization of sugar. As the body becomes more efficient with glucose metabolism, overall health is improved.

It is estimated that 47 million US residents have metabolic syndrome¹ (also referred to as insulin resistance). Insulin resistance is a complex process whereby the body loses its ability to use the insulin it secretes to metabolize blood sugar inside the cells for energy. Consequently, as this person becomes tired or fatigued, he or she feels the need to eat even more sugar. As this process escalates, sensitivity is further reduced. Blood sugar continues to rise, as does insulin production. These two factors contribute to a wide array of health problems often way before and independent of the onset of a more serious blood sugar problem diagnosed by a physician.

Reme-Flu

Reme-Flu is a unique two part homeopathic medicine for preventing and treating symptoms of flu including fever, aches and pains, chills, runny nose and cough. Reme-Flu is comprised of two individual steps. Step 1 is a homeopathic formula focused on treating general flu symptoms and is delivered in a single sub-lingual tablet. The formula for Step 2 focuses more on flu symptoms commonly associated with the respiratory system and is delivered in a sub-lingual liquid vehicle. Because respiratory symptoms can be so pronounced with the flu, the Step 2 formula is combined with unique Syn-X9 Formulation.  Syn-X9 is a special blend of homeopathic compound that enhances cellular absorption of the active ingredients. It can also help cells better expel noxious materials from the cell thereby expediting the healing process.

Reme-Flu is meant to be taken at the onset of symptoms three times a day, for a four day treatment course. For best results, the entire course of treatment should be completed according to directions. One dose should be taken in the morning, afternoon and prior to bed each day. The doses should be taken at approximately the same time each of the four days. A complete dose is comprised of taking one tablet and allowing it to dissolve completely under the tongue, followed by 20 drops of liquid to be held in the mouth for approximately 30 seconds, and then swallow.

Cinnechol™

Cinnechol™ – is the all-natural nutritional supplement designed to work in harmony with your body to help normalize cholesterol and triglyceride levels — without harmful side effects. Cinnechol’s all-natural ingredients work together to improve circulation and decrease inflammation which are vital components of heart and circulatory health.

Talsyn

Talsyn is for the serious management of Keloids, Hypertrophic Scars, Erythema, and Surgical Incisions. Talsyn has been clinically proven to facilitate healing and improve the appearance, redness, and tensile strength of scars. Talsyn is used and endorsed by leading plastic and reconstructive surgeons.

Talsyn-CI Scar Cream is a Lipid-Peptide compound with a pleasant fragrance. Talsyn-CI is a synergistic blend of several innovative fatty acids, unique peptides, and complimentary botanical extracts. It is safe to use with all clothing and will not damage or stain fabric. 

This proprietary patent pending blend of ingredients has the unique ability of penetrating deep into the layers of the skin where wound healing occurs. Synthesis of new collagen which is vital to the process of wound healing is stimulated. Other ingredients deliver anti-inflammatory and wound healing properties. Numerous nutrients in Talsyn’s botanicals help create an optimal environment for the skin to repair itself in the fastest, most efficient organized configuration; thus allowing the scar to most closely resemble its original skin integrity. Results can be seen in as little as two to four weeks. Continue use as recommended by the attending physician.

Infinitink®

Infinitink® is a high quality tattoo ink that is engineered to be permanent and safe and is far easier to remove from the skin than traditional tattoo inks. Infinitink is applied to the skin in the same way as any other tattoo. It also stays in the skin for as long as you wish. If, however, you choose to have your Infinitink tattoo removed, it will come out of the skin in fewer treatments than tattoos made with traditional inks.

Nuvilex Offerings under Development: Eco-Friendly (NOTE: From Goldman Research Report – May 10, 2011)

Citroxin™ - A patented blockbuster product, Citroxin™, looks like it will be offered later this year which could emerge as a major sales driver.  Citroxin™ is a “green” surface cleaner and sterilizer that rivals chemical cleaners.  We believe Nuvilex is in the 8^th inning of the product submission and approval with the EPA.  Once approved, Nuvilex could elect to private label the product or sell it directly to consumer, hospitals and other businesses seeking an eco-friendly alternative to current, toxic, chemical-based products.  The current market opportunity is likely $10 billion annually.

Oraphyte™ - Much like Citroxin™, Oraphyte™ is designed as an eco-friendly alternative to chemical-based products, but in this case Oraphyte™ is an all-natural nematocide.  The Oraphyte™ formula is a non-toxic; biodegradable proprietary combination of organic materials is highly effective in combating nematodes harmful to grass and other plants.  There is great demand for such a solution for lawn and crop protection and it has the potential ability to replace methyl bromide and other extremely hazardous chemicals presently being used in the US and abroad. 

Recent Key Press Releases

Thursday, May 19, 2011 - Nuvilex, Inc. in Advanced-Stage Discussions to Acquire Pancreatic Cancer Treatment Technology - SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB: NVLX) announces discussions are at an advanced stage with one of the world’s most experienced cell therapy companies to acquire their pancreatic cancer treatment technology.

The planned acquisition by Nuvilex would involve therapeutic treatment potential for pancreatic cancer, an aggressive, invasive disease responsible for 37,000 annual deaths in the U.S. alone. This acquisition will enable Nuvilex to provide encapsulated, living cells engineered to target tumors in patients with minimal collateral tissue damage. In completed clinical studies on pancreatic cancers, this treatment protocol has been shown to double life expectancy over present conventional pancreatic cancer therapy.

Pancreatic cancer is a particularly insidious form of the disease because it often does not show overt symptoms and therefore is not diagnosed until in an advanced stage. Even the best treatments for pancreatic cancer often extend life by only a few months. Less than 5% of patients diagnosed with this disease live longer than 5 years. The company’s technology for creating, maintaining, and providing the appropriate cells to combat this disease will be rapidly activated once this agreement is completed.

Dr. Robert F. Ryan, Nuvilex’s Chief Executive, stated, “We are encouraged by developments to date in these discussions and are extremely excited by the prospect of bringing this technology into Nuvilex. It has been a passion of ours to aid in the development of individualized therapies and this incredible opportunity will allow the Company to do just that. Expanding on the opportunity to provide personalized medicine for patients with appropriate needs will ultimately include other therapeutic interventions. By owning this advanced therapeutic technology, Nuvilex will become a significant player in the biotechnology arena, will dramatically open opportunities for our interaction with other companies, and will enable Nuvilex to stand out significantly from its direct competitors.”

Tuesday, May 17, 2011 - Nuvilex, Inc. Sets Aggressive Biotechnology Growth Strategy Agenda - Nuvilex, Inc. (OTCQB: NVLX), announced that it has finalized an aggressive growth strategy to pursue available opportunities within the biotech arena. The strategy, discussed by Dr. Robert F. Ryan, CEO of Nuvilex, is designed to capitalize on management expertise and existing Nuvilex technology, will combine ongoing research and product development, and will include licensing agreements and the acquisition of targeted companies within the industry.

Dr. Ryan stated, “The coming months should be very exciting as we have recently completed reorganization of our existing Divisions so the emphasis is on growth through biotechnology. New products have already been created and others will involve reformulation and redevelopment of existing products and their associated technology in addition to the acquisition of new technology that reflects this new emphasis. Acquisitions we are pursuing are in the most cutting-edge growth areas in the biotechnology arena. With all of our housecleaning finished and new, experienced management in place, we can now focus on the growth of Nuvilex and enhancing shareholder value.”

Thursday, May 12, 2011 – Nuvilex, Inc. Announces Buy Recommendation by Goldman Research - Nuvilex, Inc. announced today that Goldman Research issued a report Tuesday, May 10, 2011, stating in the title, “Nuvilex, Inc., Natural Products Leader Is An Undiscovered Gem.” Goldman also clearly recognized Nuvilex as being currently “valued for its current portfolio only, so Investors get the rest of the Company for free” and “does not reflect the expected launch of new products or the value of the pre-clinical development portfolio.” The report rates Nuvilex a Speculative Buy adding “we believe that the shares could reach $0.50 by year end.” By the end of Tuesday when the report was issued, 2.41 Million shares had traded, stimulating one of the largest and most active days of trading since the management was changed in January. Dr. Robert Ryan, President and CEO commented, “We were extremely pleased to receive such a glowing report on Nuvilex and the recognition of both the importance of stabilization and expansion as we are striving to move the Company forward.”

The research report highlighted “Nuvilex’s research and development portfolio, containing 14 issued patents, provides the Company with a major competitive advantage.” The report also looked to the future pointing out, “Nuvilex is monetizing this advantage through the release of 2 potentially eco-friendly blockbusters slated for release in the next 18 months that should immediately capture share of a combined multi-billion market opportunity.” Dr. Ryan, also stated “I am very excited that the report suggested the type of change expected for Nuvilex, namely, ‘Investors should expect to witness major hockey stick-type growth in 2011; this is what we have been, and will continue, striving hard to accomplish.”

Goldman discussed the recent milestones met by the management team as contributing to overall shareholder value, stating, “Since Dr. Ryan joined roughly three months ago, he has brought on Dr. Gerald Crabtree as COO, and overseen near term milestones which set the stage for Nuvilex to increase its shareholder value. These initiatives include:

·         New trading on the OTC QB, which has resulted in an increase in daily volume

·         Overhaul of online distribution capabilities, including the addition of new personnel to ensure sales growth

·         Introduction of new distribution relationships, operational oversight

·         Introduction of new packaging sizes in response to customer requests

Most importantly, Nuvilex has embarked on what we view as an innovative three-pronged approach. This strategy properly leverages the underlying assets of the Company (which includes 14 patents), and leads to monetization in such a fashion that Nuvilex should emerge as a leader in key segments of the natural products space and as a proprietary, biotechnology products developer.”

As an overall assessment, valuation and conclusion, the Goldman Research Report believes “Nuvilex, Inc. is poised to become a major player in multiple segments of the multi-billion dollar and natural products space. The Company is taking advantage of favorable “green energy and green products” industry drivers, its experience, innovation and scalability to build its existing lines and enter new verticals.” After recognizing Nuvilex should experience benefit from increased sales and distribution of Cinnergen, Cinnechol and Talsyn, Goldman pointed out the critical future potential, “The Company’s most recent research and development on natural anticancer agents, Alternia™, has interesting potential and may warrant a future update. Additionally, the expected 2H11 potential marketing of Citroxin™, an innovative eco-friendly, antimicrobial, sterilizer and cleanser offers huge direct and private label sales potential. Thus, unlike most firms in the sector, Nuvilex investors benefit from multiple shots on goal.”

To view, go to www.nuvilex.com and click on the special link to Goldman Research Reports.

Wednesday, May 11, 2011 - Nuvilex, Inc. Announces Favorable Initial Test Results of Natural Product Cancer Agent Alternia™ - Nuvilex, Inc., in conjunction with its subsidiary Knock-Out Technologies, Ltd. and joint venture partner Legacy Biotechnologies, Inc., report preliminary study findings undertaken with Alternia™, Nuvilex’s natural product cancer agent formulation.

Initial studies, carried out at a prestigious research center in Georgia, suggested Alternia™ had potential to cause alterations in cell division and initiate apoptosis in cancer cells, a series of events typically leading to cell death. In cancer research, agents that affect cell division and cause apoptosis, or cell death, are often studied in greater detail because they may lead to effective therapies. The potentially favorable outcomes of the initial studies prompted Nuvilex management to pursue additional testing.

As a result, the effect of Alternia™ was assessed for its effect on cancer cell line growth at a leading cancer center in Florida. Significantly, Alternia™ caused alterations in cell cycle arrest and the ability to induce apoptosis in some cell lines, indicating the need for additional studies. Preliminary animal testing was carried out at Discovery and Imaging Services (MIR), a subsidiary of Charles River Laboratories, Tier 1 specialists in pre-clinical laboratory services. Results of the animal tests provided initial information on toxicity, potential future dosages and maximum tolerated dose, providing insight into future directions for this agent. Future testing will include additional cell line and animal studies to determine specific cancer cell types which Alternia™ may be effective against and aid parameter determination for prospective clinical trials.

Nuvilex’s Chief Executive, Dr. Robert F. Ryan, commented, “We are still in the developmental stages, but initial testing with Alternia™ allows us to consider directions to advance its development. We plan to investigate it further and assess its potential for human use, as well as working to procure adequate resources, including grant acquisition, to ensure its ability to be studied. Nuvilex greatly appreciates Legacy Biotechnologies’ funding of Alternia™ testing and their role in its development, allowing us to devote primary resources to advancing existing products and sales, establishing new products and enhancing shareholder value.”

Management

Dr. Robert F. Ryan, President and CEO:

Dr. Robert F. Ryan was named President and Chief Executive Officer. Dr. Ryan has broad scientific experience in biochemistry, cell and molecular biology, human genetics, novel therapies, and basic and clinical cancer research, having received his Masters in Biochemistry, Cell and Molecular Biology at The Medical College of Georgia, studying sickle cell anemia. He received his Ph.D. in Molecular Genetics at Thomas Jefferson University characterizing DNA and RNA binding properties of zinc finger proteins. Through his extensive training, his experiences extend across the fields of aging, hemoglobinopathies, gene expression, human diseases, DNA, RNA, proteins and their interactions, stem cell research and applications, oncology, clinical protocols and therapies.

Professionally, Dr. Ryan has become a pioneer in the field of emerging biotechnology, specializing in assisting small companies with insight and bringing products to market through the rigorous FDA approval process. Since 2002, Dr. Ryan served as the Chief Executive Officer of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management, scientific guidance, FDA regulatory advice, advising investors, and investment acquisition opportunities. With 25 years experience including excellent training at the Wistar Institute, NIH, and NCI, he has participated in basic and clinical investigations and has published and edited research articles in several peer-reviewed journals.

Dr. Gerald W. Crabtree, COO:

Dr. Crabtree was recently named the Chief Operating Officer. Even in such a short period as a few weeks, he has provided a significant benefit and impact for Nuvilex, clearly matching not only the commitment to repositioning Nuvilex into the biotechnology area, but also adds to the strength of our existing products and pipeline. Dr. Ryan has worked with Dr. Crabtree and looks forward to working with him to move Nuvilex forward. He has extensive experience in the areas of natural and synthetic drug and device research and development, having worked in both academia and small and large company environments. His business and financial acumen together with his research and development background combine to make him an invaluable addition to Nuvilex.

Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles, and served as project manager for development of major oncologic agents. He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society. Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals. He is a National Cancer Institute of Canada Research Fellow. In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University. He has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation. Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions, and contracts and business plans.

Patricia Gruden, Chairman of the Board of Directors and CFO:

Ms. Patricia Gruden has made a substantial impact in many companies over the years. It was in 1995 that she became cofounder of the company that has since become Nuvilex. The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance, and everything else concerning the distribution of produce worldwide. In addition, the company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment. The company and its footprint expanded, eventually giving rise to the start of the publicly traded Nuvilex, Inc. company’s roots in 2001.

Ms. Gruden has carried out almost every job in the company over the years including developer, shipper, President, CEO, Chairman of the Board, CFO and many others. As a result, she has been intricately aware of all aspects of the company and its products throughout its history. After a short semi-retirement in 2009-10, she returned with renewed vigor and has since put in extensive effort and funding into returning the business to its former capabilities. Although her history and training has been focused in management and sales, she clearly has made substantial advances for Nuvilex.

Her training has not only included the real world experiences of running more than one company, but was well founded in her attainment of her B.S. degree in Business at the University of Oklahoma. From there, things have never been the same, propelling her to embrace every business opportunity with excitement, clarity and focus. Through the years, Patricia has had a long history of owning her own businesses, and doing so successfully, with her strengths in working with people, marketing and management. As part of her contribution and success at Nuvilex, she is President of some of the subsidiaries including Cinnergen, Inc. where she ensures organization, marketing, cash flow, and good management. Currently, Ms. Patricia Gruden is the Chairman of the Board of Directors and CFO for Nuvilex, guaranteeing a good dose of knowledge and success for the company through efficient and thoughtful oversight of the entire company and good fiscal management of our assets.

Green Baron Conclusion

Under new management that includes two doctors with tremendous experience in biochemistry, we believe Nuvilex will thrive.  Nuvilex already has a product line capable of producing respectable results.  New products under development such as Oraphyte™ and Citroxin™ could provide blockbuster potential when cleared for approval by the EPA.

However, the real excitement and buzz is going to come from the Company’s aggressive growth strategy to pursue available opportunities within the biotech arena.  The first was announced last week on Thursday, May 19^th.  Nuvilex is working with one of the world’s most experienced cell therapy companies to acquire their pancreatic cancer treatment technology.   We believe this transaction will close quickly and add tremendous attention from new investors to the stock.

A price target of .50 per share recently set by Goldman Small Cap Research may clearly be in reach, and continued strong new developments could support raising this price target further.  We suggest our members look for an entry point at or near today’s profile price.  We chose NVLX as our “2011 Stock Pick of the Year” for good reason so be sure to participate!

Contact:

7702 East Doubletree Ranch Road
Suite 300
Scottsdale, AZ 85258
Phone: (480) 348-8050

email: info@nuvilex.com